Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias
- PMID: 28283020
- PMCID: PMC5345173
- DOI: 10.1186/s12879-017-2297-9
Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias
Abstract
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) spread and infections in patients with haematological malignancies are a serious concern especially in endemic areas. Treatment failures and delay in appropriate therapy for CRKP infections are frequent and the mortality rate associated with CRKP bacteremia in neutropenic haematological patients is reported about 60%.
Methods: Haematological patients harboring CRKP hospitalized between February 2012 and May 2013 in an Italian Teaching hospital were examined. Conditions favouring CRKP spread in a haematological unit, risk factors for bacteremia in CRKP-carriers and for CRKP bacteremia-related death were evaluated in this observational retrospective study.
Results: CRKP was isolated in 22 patients, 14 (64%) had bacteremia. Control measures implementation, particularly the weekly rectal screening for CRKP performed in all hospitalized patients and contact precautions for CRKP-carriers and newly admitted patients until proved CRKP-negative, reduced significantly the CRKP spread (14 new carriers identified of 131 screened patients vs 5 of 242 after the intervention, p = 0.001). Fifty-eight percent of carriers developed CRKP bacteremia, and acute myeloid leukemia (AML) resulted independently associated with the bacteremia occurrence (p = 0.02). CRKP bacteremias developed mainly during neutropenia (86%) and in CRKP-carriers (79%). CRKP bacteremias were breakthrough in 10 cases (71%). Ten of 14 patient with CRKP bacteremias died (71%) and all had AML. The 70% of fatal bacteremias occurred in patients not yet recognized as CRKP-carriers and 80% were breakthrough. Initial adequate antibiotic therapy resulted the only independent factor able to protect against death (p = 0.02).
Conclusions: The identification of CRKP-carriers is confirmed critical to prevent CRKP spread. AML patients colonized by CRKP resulted at high risk of CRKP-bacteremia and poor outcome and the adequacy of the initial antibiotic therapy may be effective to improve survival. To limit the increase of resistance, the extensive use of antibiotics active against CRKP should be avoided, but in the setting of high CRKP pressure and high-risk CRKP-colonized haematological patients, timely empiric antibiotic combinations active against CRKP could be suggested as treatment of febrile neutropenia.
Keywords: Bacteremia; Carbapenem-resistant Klebsiella pneumoniae; Haematological malignancies; Neutropenia; Spread.
Figures
Similar articles
-
Retrospective analysis of molecular characteristics, risk factors, and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.BMC Microbiol. 2024 Aug 22;24(1):309. doi: 10.1186/s12866-024-03465-4. BMC Microbiol. 2024. PMID: 39174950 Free PMC article.
-
A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients.J Infect Dis. 2020 Mar 16;221(Suppl 2):S174-S183. doi: 10.1093/infdis/jiz559. J Infect Dis. 2020. PMID: 32176799
-
Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients.BMC Infect Dis. 2018 May 31;18(1):248. doi: 10.1186/s12879-018-3160-3. BMC Infect Dis. 2018. PMID: 29855274 Free PMC article.
-
Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis.Infect Control Hosp Epidemiol. 2017 Nov;38(11):1319-1328. doi: 10.1017/ice.2017.197. Epub 2017 Sep 27. Infect Control Hosp Epidemiol. 2017. PMID: 28950924 Review.
-
Monotherapy vs combination therapy in patients with Klebsiella pneumoniae bloodstream infection: A systematic review and meta-analysis.J Infect Chemother. 2024 May;30(5):372-378. doi: 10.1016/j.jiac.2024.02.007. Epub 2024 Feb 17. J Infect Chemother. 2024. PMID: 38369125 Review.
Cited by
-
Impact of SARS-CoV-2 on Viral Respiratory Infections in Patients with Hematological Malignancies.Viruses. 2024 Sep 26;16(10):1520. doi: 10.3390/v16101520. Viruses. 2024. PMID: 39459855 Free PMC article.
-
Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC-K. pneumoniae. A 7-Years Retrospective Observational Cohort Study.Infect Drug Resist. 2023 Jan 31;16:695-704. doi: 10.2147/IDR.S393802. eCollection 2023. Infect Drug Resist. 2023. PMID: 36747900 Free PMC article.
-
Carbapenem-Resistant Enterobacteriaceae (CRE) among Children with Cancer: Predictors of Mortality and Treatment Outcome.Antibiotics (Basel). 2023 Feb 17;12(2):405. doi: 10.3390/antibiotics12020405. Antibiotics (Basel). 2023. PMID: 36830314 Free PMC article.
-
Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.Infection. 2022 Dec;50(6):1409-1423. doi: 10.1007/s15010-022-01876-x. Epub 2022 Jul 4. Infection. 2022. PMID: 35781869 Review.
-
Carbapenem-resistant Klebsiella pneumoniae bloodstream infections in haematological malignances and hematopoietic stem cell transplantation: Clinical impact of combination therapy in a 10-year Brazilian cohort.PLoS One. 2024 Jan 26;19(1):e0297161. doi: 10.1371/journal.pone.0297161. eCollection 2024. PLoS One. 2024. PMID: 38277372 Free PMC article.
References
-
- Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96. doi: 10.1016/S1473-3099(13)70190-7. - DOI - PMC - PubMed
-
- Giani T, Pini B, Arena F, Conte V, Bracco S, Migliavacca R, the AMCLI-CRE Survey Participants, Pantosti A, Pagani L, Luzzaro F, Rossolini GM. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill. 2013;18(22):pii = 20489. Available online http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20489. - PubMed
-
- Conte V, Monaco M, Giani T, D’Ancona F, Moro ML, Arena F, D’Andrea MM, Rossolini GM, Pantosti A, on behalf of the AR-ISS Study Group on Carbapenemase-Producing K. pneumoniae Molecular Epidemiology of KPC-producing Klebsiella pneumoniae from invasive infection in Italy: increasing diversity with predominance of the ST512 clade II sublineage. J Antimicrob Chemother. 2016;71:3386–91. doi: 10.1093/jac/dkw337. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
